{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:56:18Z","timestamp":1793987778562,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02973-5","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:04:16Z","timestamp":1761905056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Benefits of glucagon-like peptide-1 receptor agonists versus pioglitazone for cardio-hepatic outcomes: a territory-wide target trial emulation"],"prefix":"10.1186","volume":"24","author":[{"given":"Lanlan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Tak-Wai","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Ho-Yi","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Sun","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Chi-Ho","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Hung-Hin","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos King-Ho","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"3","key":"2973_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S2213-8587(20)30431-9","volume":"9","author":"J Pearson-Stuttard","year":"2021","unstructured":"Pearson-Stuttard J, Bennett J, Cheng YJ, Vamos EP, Cross AJ, Ezzati M, et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021;9(3):165\u201373.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10019","key":"2973_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679\u201390.","journal-title":"Lancet"},{"issue":"12","key":"2973_CR3","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324.","journal-title":"N Engl J Med"},{"issue":"9493","key":"2973_CR4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366(9493):1279\u201389.","journal-title":"Lancet"},{"issue":"5","key":"2973_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305\u201315.","journal-title":"Ann Intern Med"},{"issue":"10","key":"2973_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2973_CR7","unstructured":"Committee ADAPP. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes\u20142025. Diabetes Care. 2024;48(Supplement_1):S59\u2013S85."},{"key":"2973_CR8","doi-asserted-by":"crossref","unstructured":"Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025.","DOI":"10.2337\/figshare.28673327"},{"issue":"3","key":"2973_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V, Ratziu V, Bugianesi E, Francque S, et al. EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"issue":"1","key":"2973_CR10","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jhep.2024.06.034","volume":"82","author":"WS Silva J\u00fanior","year":"2024","unstructured":"Silva J\u00fanior WS, Sposito AC, Godoy-Matos A. Should the new EASL-EASD-EASO Clinical Practice Guidelines on MASLD recommend pioglitazone as a MASH-targeted pharmacotherapy? J Hepatol. 2024;82(1):e21\u20132.","journal-title":"J Hepatol"},{"issue":"10","key":"2973_CR11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22(10):1999-2010.e8.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2973_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","volume":"167","author":"L Wang","year":"2024","unstructured":"Wang L, Berger NA, Kaelber DC, Xu R. Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology. 2024;167(4):689\u2013703.","journal-title":"Gastroenterology"},{"issue":"2","key":"2973_CR13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/hep.32716","volume":"77","author":"LY Mak","year":"2023","unstructured":"Mak LY, Hui RW, Lee CH, Mao X, Cheung KS, Wong DK, et al. Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes. Hepatology. 2023;77(2):606\u201318.","journal-title":"Hepatology"},{"issue":"4","key":"2973_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","volume":"184","author":"H Jang","year":"2024","unstructured":"Jang H, Kim Y, Lee DH, Joo SK, Koo BK, Lim S, et al. Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA Intern Med. 2024;184(4):375\u201383.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2973_CR15","doi-asserted-by":"publisher","first-page":"e3401","DOI":"10.1002\/dmrr.3401","volume":"37","author":"C-H Lee","year":"2021","unstructured":"Lee C-H, Lui DTW, Cheung CYY, Woo Y-C, Fong CHY, Yuen MMA, et al. Different glycaemia-related risk factors for incident Alzheimer\u2019s disease in men and women with type 2 diabetes\u2014a sex-specific analysis of the Hong Kong diabetes database. Diabetes Metab Res Rev. 2021;37(6):e3401.","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"2973_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","volume":"67","author":"KS Cheung","year":"2018","unstructured":"Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67(1):28\u201335.","journal-title":"Gut"},{"issue":"3","key":"2973_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","volume":"178","author":"MA Hern\u00e1n","year":"2025","unstructured":"Hern\u00e1n MA, Dahabreh IJ, Dickerman BA, Swanson SA. The target trial framework for causal inference from observational data: why and when is it helpful? Ann Intern Med. 2025;178(3):402\u20137.","journal-title":"Ann Intern Med"},{"issue":"6","key":"2973_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3401","volume":"37","author":"CH Lee","year":"2021","unstructured":"Lee CH, Lui DTW, Cheung CYY, Woo YC, Fong CHY, Yuen MMA, et al. Different glycaemia-related risk factors for incident Alzheimer\u2019s disease in men and women with type 2 diabetes-a sex-specific analysis of the Hong Kong diabetes database. Diabetes Metab Res Rev. 2021;37(6):e3401.","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"2973_CR19","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.37765\/ajmc.2024.89534","volume":"30","author":"JH Choe","year":"2024","unstructured":"Choe JH, Xuan S, Goldenberg A, Matian J, McCombs J, Kim RE. Medication persistence and its impact on type 2 diabetes. Am J Manag Care. 2024;30(4):e124\u201334.","journal-title":"Am J Manag Care"},{"issue":"1","key":"2973_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","volume":"10","author":"AM Peterson","year":"2007","unstructured":"Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3\u201312.","journal-title":"Value Health"},{"issue":"4","key":"2973_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, St\u00fcrmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221\u20138.","journal-title":"Curr Epidemiol Rep"},{"issue":"5","key":"2973_CR22","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/liv.15874","volume":"44","author":"W Yang","year":"2024","unstructured":"Yang W, Ebrahimi F, Romeo S, Holmer M, Vessby J, Ekstedt M, et al. Risk of major adverse liver outcomes among first-degree relatives of individuals with MASLD. Liver Int. 2024;44(5):1253\u201364.","journal-title":"Liver Int"},{"issue":"1","key":"2973_CR23","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1038\/s41598-024-84985-x","volume":"15","author":"A Mader","year":"2025","unstructured":"Mader A, Haeberli D, Larcher B, Dopheide JF, Saely CH, Heinzle CF, et al. Contribution of type 2 diabetes to major adverse cardiovascular events (MACE) in a long-term observational study with different stages of atherosclerosis. Sci Rep. 2025;15(1):2792.","journal-title":"Sci Rep"},{"issue":"1","key":"2973_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0962280217713032","volume":"28","author":"C Leyrat","year":"2019","unstructured":"Leyrat C, Seaman SR, White IR, Douglas I, Smeeth L, Kim J, et al. Propensity score analysis with partially observed covariates: how should multiple imputation be used? Stat Methods Med Res. 2019;28(1):3\u201319.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"2973_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","volume":"7","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Kim HJ, Lonjon G, Zhu Y. Balance diagnostics after propensity score matching. Ann Transl Med. 2019;7(1):16.","journal-title":"Ann Transl Med"},{"issue":"1","key":"2973_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1756283X10385964","volume":"4","author":"HB El-Serag","year":"2011","unstructured":"El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol. 2011;4(1):5\u201310.","journal-title":"Therap Adv Gastroenterol"},{"issue":"18","key":"2973_CR27","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579\u201388.","journal-title":"Circulation"},{"issue":"12","key":"2973_CR28","doi-asserted-by":"publisher","first-page":"e2349856\u2013e","DOI":"10.1001\/jamanetworkopen.2023.49856","volume":"6","author":"S Bea","year":"2023","unstructured":"Bea S, Jeong HE, Filion KB, Yu OH, Cho YM, Lee BH, et al. Outcomes of SGLT-2i and GLP-1RA therapy among patients with type 2 diabetes and varying NAFLD status. JAMA Netw Open. 2023;6(12):e2349856-e.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2973_CR29","doi-asserted-by":"publisher","first-page":"e019463","DOI":"10.1161\/JAHA.120.019463","volume":"10","author":"YH Teo","year":"2021","unstructured":"Teo YH, Teo YN, Syn NL, Kow CS, Yoong CSY, Tan BYQ, et al. Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc. 2021;10(5):e019463.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2973_CR30","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0962280217735560","volume":"28","author":"S Dodd","year":"2019","unstructured":"Dodd S, Williamson P, White IR. Adjustment for treatment changes in epilepsy trials: a comparison of causal methods for time-to-event outcomes. Stat Methods Med Res. 2019;28(3):717\u201333.","journal-title":"Stat Methods Med Res"},{"issue":"7","key":"2973_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503\u20138.","journal-title":"Dig Liver Dis"},{"key":"2973_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332687","author":"S Bea","year":"2024","unstructured":"Bea S, Ko HY, Bae JH, Cho YM, Chang Y, Ryu S, et al. Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2024. https:\/\/doi.org\/10.1136\/gutjnl-2024-332687.","journal-title":"Gut"},{"issue":"3","key":"2973_CR33","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3350\/cmh.2022.0330","volume":"29","author":"MJ Park","year":"2023","unstructured":"Park MJ, Kim H, Kim MG, Kim K. Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis. Clin Mol Hepatol. 2023;29(3):693\u2013704.","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"2973_CR34","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00392-023-02362-6","volume":"113","author":"A Villaschi","year":"2024","unstructured":"Villaschi A, Ferrante G, Cannata F, Pini D, Pagnesi M, Corrada E, et al. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis. Clin Res Cardiol. 2024;113(6):898\u2013909.","journal-title":"Clin Res Cardiol"},{"issue":"Suppl 2(Suppl 2","key":"2973_CR35","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.2337\/dcS13-2031","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner G, Currie CJ, Schernthaner GH. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care. 2013;36(Suppl 2(Suppl 2)):S155\u201361.","journal-title":"Diabetes Care"},{"issue":"4","key":"2973_CR36","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.ahj.2007.11.029","volume":"155","author":"R Wilcox","year":"2008","unstructured":"Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone clinical trial in macro vascular events (PROactive 10). Am Heart J. 2008;155(4):712\u20137.","journal-title":"Am Heart J"},{"issue":"10","key":"2973_CR37","first-page":"e46911","volume":"15","author":"IM Sheikh","year":"2023","unstructured":"Sheikh IM, Hassan OA, Adam SM, Ali AI, Ogedegbe OJ, Tabowei G, et al. Association of pioglitazone with major adverse cardiovascular events, all-cause mortality, and heart failure hospitalizations: a systematic review. Cureus. 2023;15(10):e46911.","journal-title":"Cureus"},{"issue":"17","key":"2973_CR38","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of Glucagon-like peptide receptor agonists and Sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022\u201331.","journal-title":"Circulation"},{"issue":"1","key":"2973_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12933-021-01294-7","volume":"20","author":"L Nesti","year":"2021","unstructured":"Nesti L, Tric\u00f2 D, Mengozzi A, Natali A. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol. 2021;20(1):109.","journal-title":"Cardiovasc Diabetol"},{"issue":"10456","key":"2973_CR40","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949\u201361.","journal-title":"Lancet"},{"key":"2973_CR41","doi-asserted-by":"publisher","first-page":"1357309","DOI":"10.3389\/fphar.2025.1357309","volume":"16","author":"HF Azhari","year":"2025","unstructured":"Azhari HF, Dawson J. Clinical implications of fracture severity risk with pioglitazone: a systematic review and meta-analysis of clinical randomized trials. Front Pharmacol. 2025;16:1357309.","journal-title":"Front Pharmacol"},{"issue":"6","key":"2973_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.13110","volume":"8","author":"T Miwa","year":"2024","unstructured":"Miwa T, Tajirika S, Imamura N, Adachi M, Horita R, Hanai T, et al. Usefulness of health checkup-based indices in identifying metabolic dysfunction-associated steatotic liver disease. JGH Open. 2024;8(6):e13110.","journal-title":"JGH Open"},{"issue":"10","key":"2973_CR43","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/apt.12963","volume":"40","author":"L Fedchuk","year":"2014","unstructured":"Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40(10):1209\u201322.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02973-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:04:19Z","timestamp":1761905059000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02973-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2973"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02973-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of the Institutional Review Board of the University of Hong Kong\/Hospital Authority Hong Kong West Cluster (Reference Number: UW 15-613). Informed consent was not required as all data was anonymous.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.H.L received advisory board and lecture honorarium from AstraZeneca, Bayer, Boehringer Ingelheim, Echosens, Eli Lilly, Gilead, GSK, Novo Nordisk and Sanofi Aventis. C.K.H.W and X.X were supported by the AIR@InnoHK administered by Innovation and Technology Commission, Government of Hong Kong Special Administrative Region, China.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"416"}}